Anupam Rasayan Q2FY27: Revenue ₹821 Cr, PAT ₹65 Cr; Acquires Bliss GVS Pharma
Anupam Rasayan reported Q2 FY27 consolidated revenue of ₹821 Cr, up 23% QoQ, with PAT at ₹65 Cr (up 27% QoQ). H1 FY27 consolidated revenue grew 21% YoY to ₹1,489 Cr. The company acquired a 50.07% stake in Bliss GVS Pharma and signed a six-year supply contract with a US specialty metal manufacturer.
The financial results show robust growth. The acquisition of Bliss GVS Pharma is a significant strategic move into finished dosage formulations, and the long-term contract with a US specialty metal manufacturer diversifies the business into a new sector.
The company reported strong year-on-year and quarter-on-quarter growth in revenue, EBITDA, and PAT. The acquisition of Bliss GVS Pharma and a long-term supply contract with a US manufacturer are positive strategic developments.
Anupam Rasayan India Limited has announced its financial results for the second quarter and half-year ended September 30, 2026. The company reported a consolidated revenue of ₹821 crore for Q2 FY27, marking a 23% increase quarter-on-quarter (QoQ). Consolidated EBITDA stood at ₹202 crore (up 16% QoQ), and Profit After Tax (PAT) was ₹65 crore (up 27% QoQ).
For the standalone results, revenue increased by 23% QoQ to ₹413 crore, with EBITDA at ₹141 crore (up 22% QoQ) and PAT at ₹46 crore (up 43% QoQ).
In the half-year ended September 30, 2026, consolidated revenue grew by 21% year-on-year (YoY) to ₹1,489 crore, while consolidated EBITDA saw a substantial 38% YoY increase to ₹377 crore. Consolidated PAT for H1 FY27 was ₹116 crore, a 10% YoY growth.
Key operational highlights include the acquisition of a 50.07% controlling stake in Bliss GVS Pharma Limited, completed on September 28, 2026. This strategic move marks the company's entry into Finished Dosage Formulations (FDF) and strengthens its global pharmaceutical presence.
Anupam Rasayan also signed a six-year long-term supply contract with a leading US-based global specialty metal manufacturer, marking an entry into the geological resources sector. The company also strengthened its strategic investment in Tanfac Industries.
Mr. Anand S Desai, Managing Director, stated that H1 FY27 was marked by steady progress, expansion into new end markets, and continued strengthening of the business portfolio. He highlighted the highest-ever quarterly consolidated revenue in Q2 FY27 and the successful acquisition of Bliss GVS Pharma as significant steps in building a diversified pharmaceutical platform.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.